BiomX (PHGE) Other financing activities (2018 - 2026)
BiomX (PHGE) posted Other financing activities of $2.6 million for Q1 2026, up 271.33% sequentially from -$1.5 million in Q4 2025, and down 42.11% YoY from $4.5 million in Q1 2025.
BiomX (PHGE) Other financing activities (2018 - 2026) Analysis & Trends
BiomX has reported Other financing activities for 8 years, with the latest figure at $2.6 million in Q1 2026.
- Quarterly Other financing activities fell 42.11% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 75.9% YoY) and the FY2025 annual result came in at $3.0 million, down 89.56% from the prior year.
- Other financing activities climbed to $2.6 million in Q1 2026 per PHGE's latest filing, from -$1.5 million in the prior quarter.
- Over five years, Other financing activities peaked at $50.0 million in Q1 2024 and troughed at -$28.7 million in Q2 2024.
- A 4-year average of $7.9 million and a median of $3.6 million in 2025 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 3303.68% in 2024, down 577.71% in 2024.
- Over 4 years, Other financing activities stood at $6.0 million in 2023, then surged by 377.71% to $28.7 million in 2024, then sank by 105.33% to -$1.5 million in 2025, then soared by 271.33% to $2.6 million in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $2.6 million, -$1.5 million, and $4.5 million for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | BiomX | 361,408.40 | -806,591.60 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.62 Mn |
| Mar 31, 2026 | 2.62 Mn |
| Dec 31, 2025 | -1.53 Mn |
| Dec 31, 2025 | -1.53 Mn |
| Mar 31, 2025 | 4.53 Mn |
| Mar 31, 2025 | 4.53 Mn |
| Dec 31, 2024 | 28.74 Mn |
| Dec 31, 2024 | 28.74 Mn |
| Jun 30, 2024 | -28.74 Mn |
| Jun 30, 2024 | -28.74 Mn |
| Mar 15, 2024 | 50.00 Mn |
| Mar 15, 2024 | 50.00 Mn |
| Jun 30, 2023 | 6.02 Mn |
| Jun 30, 2023 | 6.02 Mn |
| Mar 31, 2023 | 1.47 Mn |
| Mar 31, 2023 | 1.47 Mn |
| Dec 31, 2021 | 3.97 Mn |
| Dec 31, 2021 | 3.97 Mn |
| Sep 30, 2021 | 13.67 Mn |
| Sep 30, 2021 | 13.67 Mn |